Cargando…

Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy

Lung cancer remains the leading cause of cancer death worldwide despite the significant progress made by immune checkpoint inhibitors, including programmed death receptor-1 (PD1)/PD ligand 1 (PDL1)-blockade therapy. PD1/PDL1−blockade has achieved unprecedented tumor regression in some patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poznanski, Sophie M, Ritchie, Tyrah M, Fan, Isabella Y, El-Sayes, Abdullah, Portillo, Ana L, Ben-Avi, Ronny, Rojas, Eduardo A, Chew, Marianne V, Shargall, Yaron, Ashkar, Ali A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825270/ https://www.ncbi.nlm.nih.gov/pubmed/33479024 http://dx.doi.org/10.1136/jitc-2020-001933

Ejemplares similares

Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
por: Davies, John S, et al.
Publicado: (2022)

Adaptive single-KIR(+)NKG2C(+) NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia
por: Haroun-Izquierdo, Alvaro, et al.
Publicado: (2022)

Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
por: Liu, Dan, et al.
Publicado: (2021)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Intermediate monocytes induced by IFN-γ inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27
por: Wang, Rikang, et al.
Publicado: (2022)

PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
por: Yamaguchi, Yukiko, et al.
Publicado: (2022)

TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
por: Bi, Jiacheng, et al.
Publicado: (2023)

Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy
por: Prokopi, Anastasia, et al.
Publicado: (2021)

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
por: Morton, Laura T, et al.
Publicado: (2022)

Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
por: Stromnes, Ingunn M, et al.
Publicado: (2022)

CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
por: Li, Feng, et al.
Publicado: (2020)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
por: Guo, Xuan, et al.
Publicado: (2021)

TNFR2 blockade of regulatory T cells unleashes an antitumor immune response after hematopoietic stem-cell transplantation
por: Moatti, Audrey, et al.
Publicado: (2022)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Synergistic therapeutic combination with a CAF inhibitor enhances CAR-NK-mediated cytotoxicity via reduction of CAF-released IL-6
por: Lee, Young Eun, et al.
Publicado: (2023)

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
por: Tvingsholm, Siri Amanda, et al.
Publicado: (2023)

Adoptive transfer of zoledronate-expanded autologous Vγ9Vδ2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study
por: Kakimi, Kazuhiro, et al.
Publicado: (2020)

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

Dual oxidase 1 limits the IFNγ-associated antitumor effect of macrophages
por: Meziani, Lydia, et al.
Publicado: (2020)

Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes
por: Marotte, Lucine, et al.
Publicado: (2020)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1(157-165) tumor-specific peptide
por: Shenderov, Eugene, et al.
Publicado: (2021)

Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response
por: Wang, Yi-Na, et al.
Publicado: (2023)

Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes
por: Arranz-Nicolás, Javier, et al.
Publicado: (2020)

PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells
por: Bajor, Malgorzata, et al.
Publicado: (2022)

AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survival
por: Mehra, Vedika, et al.
Publicado: (2023)

Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma
por: Yu, Zhuo, et al.
Publicado: (2022)

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
por: Ishihara, Mikiya, et al.
Publicado: (2022)

Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers
por: Jiménez-Reinoso, Anaïs, et al.
Publicado: (2022)

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy
por: Plewa, Natalia, et al.
Publicado: (2023)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia
por: Trad, Rim, et al.
Publicado: (2022)

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
por: Lontos, Konstantinos, et al.
Publicado: (2023)

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
por: van Amerongen, Rosa A, et al.
Publicado: (2022)

4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells
por: Roselli, Emiliano, et al.
Publicado: (2021)

IFN-γ- and IL-17-producing CD8(+) T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity
por: Ohkuri, Takayuki, et al.
Publicado: (2021)

Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
por: Iida, Yuichi, et al.
Publicado: (2020)

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor
por: Gao, Ge, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pikc51sklcr2186kojdkiht3j6